statistiche ricercatore

DENTALI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	25.096
EU - Europa	13.118
AS - Asia	3.338
Continente sconosciuto - Info sul continente non disponibili	33
SA - Sud America	29
OC - Oceania	8
AF - Africa	5
Totale	41.627

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	25.068
IT - Italia	6.778
UA - Ucraina	2.279
TR - Turchia	1.607
SE - Svezia	1.186
IE - Irlanda	797
DE - Germania	766
VN - Vietnam	731
CN - Cina	594
FI - Finlandia	509
GB - Regno Unito	419
SG - Singapore	297
FR - Francia	194
RU - Federazione Russa	59
IN - India	44
EU - Europa	29
JP - Giappone	27
CA - Canada	24
BE - Belgio	23
NL - Olanda	23
CZ - Repubblica Ceca	17
BR - Brasile	14
CL - Cile	11
ES - Italia	9
PT - Portogallo	8
AU - Australia	7
CH - Svizzera	7
RO - Romania	7
AT - Austria	6
GR - Grecia	6
HK - Hong Kong	5
HU - Ungheria	4
IR - Iran	4
TH - Thailandia	4
A2 - ???statistics.table.value.countryCode.A2???	3
AL - Albania	3
AR - Argentina	3
EG - Egitto	3
ID - Indonesia	3
IL - Israele	3
MY - Malesia	3
NO - Norvegia	3
PK - Pakistan	3
PL - Polonia	3
DK - Danimarca	2
HN - Honduras	2
KR - Corea	2
LI - Liechtenstein	2
RS - Serbia	2
SI - Slovenia	2
TW - Taiwan	2
A1 - Anonimo	1
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
CR - Costa Rica	1
KW - Kuwait	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LK - Sri Lanka	1
LT - Lituania	1
MD - Moldavia	1
MX - Messico	1
NG - Nigeria	1
NZ - Nuova Zelanda	1
PE - Perù	1
PH - Filippine	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
UZ - Uzbekistan	1
ZA - Sudafrica	1
Totale	41.627

Salva come PNG Salva come JPEG

Città	#
Milan	4.990
Fairfield	4.108
Woodbridge	2.671
Ashburn	2.022
Houston	1.922
Jacksonville	1.808
Seattle	1.604
Wilmington	1.492
Chandler	1.387
Cambridge	1.384
Ann Arbor	1.312
Izmir	813
Dublin	792
Princeton	787
Dearborn	591
Nyköping	539
Boardman	496
Dong Ket	367
Rome	313
Singapore	288
San Diego	243
San Mateo	159
Ogden	152
Beijing	127
Como	126
Chicago	119
Washington	102
London	95
Santa Clara	74
New York	72
Düsseldorf	70
Hefei	62
Redmond	62
Nanjing	59
Los Angeles	58
Helsinki	56
Norwalk	53
Kunming	50
Verona	48
Kocaeli	39
Paris	37
Dallas	31
Kilburn	30
Jinan	29
Munich	25
Nanchang	24
Frankfurt am Main	23
Tokyo	22
Besana In Brianza	20
Falls Church	19
Ponte Lambro	19
Redwood City	19
Brussels	18
Guangzhou	18
Prescot	18
Fuzhou	17
Chiswick	16
Toronto	16
Brno	15
Acton	14
Indiana	14
Shenyang	14
Varese	14
Berlin	13
Philadelphia	13
Bergamo	12
Hounslow	12
Wandsworth	11
Busto Arsizio	10
Hebei	10
New Bedfont	10
San Francisco	10
Southwark	10
Wuhan	10
Xian	10
Changsha	9
Islington	9
Pune	9
Phoenix	8
Ralingen	8
Suresnes	8
São Paulo	8
Zhengzhou	8
Chongqing	7
Magnago	7
Ningbo	7
Torino	7
Abbiategrasso	6
Detroit	6
Genoa	6
Hangzhou	6
Legnano	6
Saint Louis	6
Amsterdam	5
Andover	5
Baotou	5
Brescia	5
Cleveland	5
Lappeenranta	5
Novara	5
Totale	32.281

Salva come PNG Salva come JPEG

Nome	#
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	226
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	224
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	220
Risk of recurrence of unusual site venous thromboembolism	213
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	203
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis	194
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	194
Optimal treatment duration of venous thrombosis	190
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	189
Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature	189
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	188
Patient selection for thromboprophylaxis in medical inpatients	186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	185
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	183
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	180
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	179
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	179
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	178
Venous ischemic syndromes	178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	176
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	175
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	174
Warfarin interactions with antibiotics in the ambulatory care setting	171
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	171
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	171
Duration of anticoagulation after venous thromboembolism in real world clinical practice	170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	170
Venous and arterial thrombosis in patients with HIV infection	168
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens	168
Seasonal and monthly variation in occurrence of hypertensive urgency	167
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	166
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation	164
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	163
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	163
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	163
Statins and secondary prevention of ischemic and hemorrhagic stroke	162
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	160
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	160
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	160
ABO blood group and vascular disease: an update	160
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	158
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	156
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	156
Is diabetes a hypercoagulable state? A critical appraisal	156
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	155
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	155
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	155
sRAGE and early signs of cardiac target organ damage in mild hypertensives	155
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	155
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment	154
Prevention of in-hospital VTE: why can't we do better?	153
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	153
How I treat splanchnic vein thrombosis	152
The role of thrombolytic therapy in pulmonary embolism	152
Statins for acute ischemic stroke	152
In vitro effects of Apixaban on 5 different cancer cell lines	151
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal	150
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action.	150
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis.	149
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: Comment	149
In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: A sex effect?	149
The effect of thyroid autoantibodies on warfarin stability	149
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study	148
Italian intersociety consensus on DOAC use in internal medicine	147
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience	146
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes	146
Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: Results of a patient-level meta-analysis	146
Direct oral anticoagulants for superficial-vein thrombosis	145
The prevention and treatment of venous thromboembolism in pregnancy	145
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism.	144
Management of hypertension in overweight and obese patients: a practical guide for clinicians.	144
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening	144
Neutrophil-to-lymphocyte ratio: A new prognostic factor even in patients with heart failure	144
Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study	143
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy	143
Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence	143
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study	142
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	142
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.	142
Risk of Thromboembolism, Recurrent Hemorrhage, and Death after Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding	142
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.	141
Nonadherence with INR monitoring and anticoagulant complications	141
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism	141
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.	139
Natural anticoagulants deficiency and the risk of venous thromboembolism: A meta-analysis of observational studies	139
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.	138
Statins, fibrates, and venous thromboembolism: a meta-analysis.	137
Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant or antiplatelet drugs	137
The role of the metabolic syndrome in patients with provoked venous thromboembolic events	137
Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry	137
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.	136
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging.	136
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients	136
JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease.	135
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature	135
Totale	16.090

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	173.816
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	173.816

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	7.603	0	0	0	1.754	653	965	1.231	1.043	721	571	169	496
2020/2021	7.056	145	653	766	695	409	732	291	619	838	458	574	876
2021/2022	4.033	403	544	187	104	219	172	325	215	229	726	411	498
2022/2023	4.345	480	206	318	379	303	956	14	560	651	238	132	108
2023/2024	8.113	1.241	1.276	1.284	1.554	1.634	559	57	105	238	74	32	59
2024/2025	1.293	36	47	1.117	93	0	0	0	0	0	0	0	0
Totale													42.145